<DOC>
	<DOC>NCT00603993</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of subcutaneous (SC) self-injections (by the subject or subject's family member) of adalimumab in adult Japanese subjects with Rheumatoid Arthritis in an open-label study.</brief_summary>
	<brief_title>Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Completed Week 36 of Study M03651 [NCT 00235872] Wish to participate in selfinjection study Give written informed consent Comply with protocol requirements Subject develops serious adverse events at time of eligibility confirmation Subject develops severe infections requiring hospitalization or IV injection of antibiotics within 28 days before eligibility confirmation Subject develops infections requiring oral administration of antibiotics within 14 days before eligibility confirmation The investigator considers the subject inappropriate for participation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>